Literature DB >> 19929137

Application of proteomics in biomarker discovery: a primer for the clinician.

V Tambor1, A Fucíková, J Lenco, M Kacerovský, V Rehácek, J Stulík, R Pudil.   

Abstract

Ever since proteomics was proven to be capable of characterizing a large number of differences in both protein quality and quantity, it has been applied in various areas of biomedicine, ranging from the deciphering molecular pathogenesis of diseases to the characterization of novel drug targets and the discovery of potential diagnostic biomarkers. Indeed, the biomarker discovery in human plasma is clearly one of the areas with enormous potential. However, without proper planning and implementation of specific techniques, the efforts and expectations may very easily be hampered. Numerous earlier projects aimed at clinical proteomics, characterized by exaggerated enthusiasm, often underestimated some principal obstacles of plasma biomarker discovery. Consequently, ambiguous and insignificant results soon led to a more critical view in this field. In this article, we critically review the current state of proteomic approaches for biomarker discovery and validation, in order to provide basic information and guidelines for both clinicians and researchers. These need to be closely considered prior to initiation of a project aimed at plasma biomarker discovery. We also present a short overview of recent applications of clinical proteomics in biomarker discovery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19929137

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  15 in total

Review 1.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Biomarker Development for Brain-Based Disorders: Recent Progress in Psychiatry.

Authors:  James O Ebot Enaw; Alicia K Smith
Journal:  J Neurol Psychol       Date:  2013-11-01

Review 3.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

Review 4.  Proteomics: Clinical and research applications in respiratory diseases.

Authors:  Katy C Norman; Bethany B Moore; Kelly B Arnold; David N O'Dwyer
Journal:  Respirology       Date:  2018-08-13       Impact factor: 6.424

5.  Proteomic technologies for the study of osteosarcoma.

Authors:  Stephanie D Byrum; Charity L Washam; Corey O Montgomery; Alan J Tackett; Larry J Suva
Journal:  Sarcoma       Date:  2012-03-06

6.  Amniotic fluid cathelicidin in PPROM pregnancies: from proteomic discovery to assessing its potential in inflammatory complications diagnosis.

Authors:  Vojtech Tambor; Marian Kacerovsky; Ctirad Andrys; Ivana Musilova; Helena Hornychova; Lenka Pliskova; Marek Link; Jiri Stulik; Juraj Lenco
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

7.  Potential Peripartum Markers of Infectious-Inflammatory Complications in Spontaneous Preterm Birth.

Authors:  Vojtech Tambor; Marie Vajrychova; Marian Kacerovsky; Marek Link; Petra Domasinska; Ramkumar Menon; Juraj Lenco
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

Review 8.  Mass spectrometry as a tool for studying autism spectrum disorder.

Authors:  Alisa G Woods; Armand G Ngounou Wetie; Izabela Sokolowska; Stefanie Russell; Jeanne P Ryan; Tanja Maria Michel; Johannes Thome; Costel C Darie
Journal:  J Mol Psychiatry       Date:  2013-05-21

9.  Biomarker development for non-invasive prenatal diagnosis of fetal aneuploidies: predictive reliability and potential clinical application.

Authors:  Aggeliki Kolialexi; Athanasios K Anagnostopoulos; Georgia Tounta; Aris Antsaklis; Ariadni Mavrou; George Th Tsangaris
Journal:  EPMA J       Date:  2011-05-18       Impact factor: 6.543

10.  A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS-A pilot study.

Authors:  Anita Rana; Ranjana W Minz; Ritu Aggarwal; Sadhna Sharma; Neelam Pasricha; Shashi Anand; Surjit Singh
Journal:  Pediatr Rheumatol Online J       Date:  2012-08-17       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.